Ir para o conteúdo principal

Vitrafy Life Sciences Ltd (ASX: VFY) — Perfil da empresa, notícias e dados financeiros

Logo de Vitrafy Life Sciences Ltd
VFY Vitrafy Life Sciences Ltd
Imagem de banner da empresa
Perfil da empresa

Vitrafy Life Sciences Ltd

Vitrafy Life Sciences Ltd is a biotechnology company that develops controlled-rate freezing hardware and intelligent cloud software for cryopreservation workflows. The company's ecosystem integrates precision-engineered freezing equipment with cloud-based software to preserve biological materials, including human blood platelets, cell and gene therapy T-cells, and animal reproductive materials. Vitrafy serves clinical healthcare, life sciences research, combat casualty care, and aquaculture industries by providing automated, liquid-nitrogen-free cryopreservation technology designed to maintain post-thaw viability and streamline bio-material supply chains across global research and medical facilities.

Resumo

Public AUParticipação acionária
2017Ano de fundação
11–50Funcionários
Melbourne, AustraliaSede
Carregando mapa...
Presença global

Operações

Produtos e/ou serviços de Vitrafy Life Sciences Ltd

  • Precision Controlled Freezing Hardware: Custom-engineered hardware delivering rapid, liquid-nitrogen-free cryogenic freezing with high throughput per hour, reaching target cryogenic temperatures under five minutes to preserve cell viability during cryopreservation.
  • Intelligent Cryopreservation Software: Cloud-connected workflow management software that monitors, tracks, and logs cryopreservation data in real time, standardizing freezing protocols and ensuring complete chain-of-custody tracking across biological sample lifecycles.
  • Blood and Platelet Cryopreservation Solutions: Specialized freezing technology designed for human blood services and combat casualty care, improving post-thaw recovery rates of blood platelets to eliminate wash steps and extend clinical shelf life.
  • Cell and Gene Therapy Processing: Advanced cryopreservation workflows for cell therapy developers, ensuring post-thaw viability of fragile T-cells comparable to fresh samples to streamline complex therapy manufacturing and supply chains.
  • Animal Reproduction and Aquaculture Applications: Cryogenic preservation solutions tailored for livestock breeding programs and aquaculture operations, enhancing post-thaw sperm quality and fertilization success rates across commercial aquatic and terrestrial animal species.
  • Research and Optimization Services: Advisory and testing services for biotechnology laboratories and research institutions, optimizing bio-material freezing protocols and validating cryopreservation workflows to improve post-thaw quality at commercial scale.

equipe executiva do Vitrafy Life Sciences Ltd

  • Brenton Michael Leslie OwensCo-Founder, MD, CEO & Executive Director
  • Simon Thomas MartinChief Financial Officer
  • Heather PidcokeChief Science Officer
  • Timothy P. CostelloEVP& Chief Commercial Officer
  • Michael SapountzisCompany Secretary

Comunicados recentes

O que a Vitrafy Life Sciences Ltd (VFY) comunicou ao mercado, do mais recente para o mais antigo.

  1. Results of 2026 Annual General Meeting
  2. 2026 Annual General Meeting Addresses & PresentationFato relevante
  3. Release of Securities from Mandatory Escrow
  4. Quarterly Investor Briefing Presentation
  5. Q1 FY27 Quarterly Activities Report and Appendix 4CFato relevante
  6. Vitrafy Q1 FY27 Investor Briefing
  7. Investor Roadshow Presentation
  8. Change to CEO Remuneration and Employment Terms

Principais indicadores financeiros

Resultados divulgados pela Vitrafy Life Sciences Ltd, em AUD.

Cap. de mercado
176,1 mi
Receita (TTM)
209 mil
P/L
—
LPA (diluído, TTM)
-0.3
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Vitrafy Life Sciences Ltd
Fim do ano fiscalReceitaResultado operacionalLucro líquido
168,7 mil-20,4 mi-16,2 mi
65,1 mil-16,6 mi-32,7 mi
37 mil-10,7 mi-10,4 mi
32 mil-9,2 mi-7,8 mi